Literature DB >> 35661323

Neuronal GPER Participates in Genistein-Mediated Neuroprotection in Ischemic Stroke by Inhibiting NLRP3 Inflammasome Activation in Ovariectomized Female Mice.

Shiquan Wang1, Zhen Zhang1, Jin Wang1, Lina Ma1, Jianshuai Zhao1, Jiajia Wang1, Zongping Fang1, Wugang Hou2, Haiyun Guo3.   

Abstract

Estrogen replacement therapy (ERT) is potentially beneficial for the prevention and treatment of postmenopausal cerebral ischemia but inevitably increases the risk of cerebral hemorrhage and breast cancer when used for a long period of time. Genistein, a natural phytoestrogen, has been reported to contribute to the recovery of postmenopausal ischemic stroke with reduced risks. However, the underlying mechanism of genistein-mediated neuroprotection remains unclear. We reported that genistein exerted significant neuroprotective effects by enhancing the expression of neuronal G protein-coupled estrogen receptor (GPER) in the ischemic penumbra after cerebral reperfusion in ovariectomized (OVX) mice, and this effect was achieved through GPER-mediated inhibition of nod-like receptor protein 3 (NLRP3) inflammasome activation. In addition, we found that peroxisome proliferator-activated receptor-gamma coactivator 1α (PGC-1α) was the pivotal molecule that participated in GPER-mediated inhibition of NLRP3 inflammasome activation in OVX mice after ischemia/reperfusion (I/R) injury. Our data suggest that the neuronal GPER/PGC-1α pathway plays an important role in genistein-mediated neuroprotection against I/R injury in OVX mice.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  GPER; Genistein; Ischemic stroke; NLRP3; Ovariectomized mice

Mesh:

Substances:

Year:  2022        PMID: 35661323     DOI: 10.1007/s12035-022-02894-4

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.682


  33 in total

Review 1.  Hormone therapy to prevent disease and prolong life in postmenopausal women.

Authors:  D Grady; S M Rubin; D B Petitti; C S Fox; D Black; B Ettinger; V L Ernster; S R Cummings
Journal:  Ann Intern Med       Date:  1992-12-15       Impact factor: 25.391

Review 2.  Estrogens as neuroprotectants: Estrogenic actions in the context of cognitive aging and brain injury.

Authors:  E B Engler-Chiurazzi; C M Brown; J M Povroznik; J W Simpkins
Journal:  Prog Neurobiol       Date:  2016-02-15       Impact factor: 11.685

Review 3.  Stroke in women: disparities and outcomes.

Authors:  Rebecca W Persky; Lisa Christine Turtzo; Louise D McCullough
Journal:  Curr Cardiol Rep       Date:  2010-01       Impact factor: 2.931

Review 4.  Genistein: Its role in metabolic diseases and cancer.

Authors:  Vidya Mukund; Dhruv Mukund; Vinay Sharma; Mastan Mannarapu; Afroz Alam
Journal:  Crit Rev Oncol Hematol       Date:  2017-09-12       Impact factor: 6.312

Review 5.  Genistein: mechanisms of action for a pleiotropic neuroprotective agent in stroke.

Authors:  Derek A Schreihofer; Anthony Oppong-Gyebi
Journal:  Nutr Neurosci       Date:  2017-10-24       Impact factor: 4.994

6.  Distribution and characterization of estrogen receptor G protein-coupled receptor 30 in the rat central nervous system.

Authors:  Eugen Brailoiu; Siok L Dun; G Cristina Brailoiu; Keisuke Mizuo; Larry A Sklar; Tudor I Oprea; Eric R Prossnitz; Nae J Dun
Journal:  J Endocrinol       Date:  2007-05       Impact factor: 4.286

7.  Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol.

Authors:  Howard N Hodis; Wendy J Mack; Victor W Henderson; Donna Shoupe; Matthew J Budoff; Juliana Hwang-Levine; Yanjie Li; Mei Feng; Laurie Dustin; Naoko Kono; Frank Z Stanczyk; Robert H Selzer; Stanley P Azen
Journal:  N Engl J Med       Date:  2016-03-31       Impact factor: 91.245

8.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

9.  Breast cancer and hormone-replacement therapy in the Million Women Study.

Authors:  Valerie Beral
Journal:  Lancet       Date:  2003-08-09       Impact factor: 79.321

Review 10.  Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes.

Authors:  Mathew J Reeves; Cheryl D Bushnell; George Howard; Julia Warner Gargano; Pamela W Duncan; Gwen Lynch; Arya Khatiwoda; Lynda Lisabeth
Journal:  Lancet Neurol       Date:  2008-08-21       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.